68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy;68Ga-PSMA-PET/CT-basierte Strahlentherapie beim lokal rezidivierten und oligometastasierten Prostatakarzinom : Frühe Effektivität nach Primärtherapie

Strahlentherapie und Onkologie

Volumn 192, Issue 7, 2016, Pages 431-439

  Henkenberens, Christoph ^a   von Klot, Christoph A ^a   Ross, Tobias L ^a   Bengel, Frank M ^a   Wester, Hans Jürgen ^b   Merseburger, Axel S ^c   Vogel Claussen, Jens ^a   Christiansen, Hans ^a   Derlin, Thorsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Androgen deprivation therapy; Local control; Neoplasm recurrence, local; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND; TUMOR MARKER;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; CONFORMAL RADIOTHERAPY; DIARRHEA; DYSURIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; OVERALL SURVIVAL; PET-CT SCANNER; PROSTATE CANCER; RADIATION FIELD; RADIATION INJURY; RETROSPECTIVE STUDY; SPINE METASTASIS; VERY ELDERLY; WHOLE BODY PET; ADJUVANT RADIOTHERAPY; BLOOD; CLINICAL TRIAL; IMAGE GUIDED RADIOTHERAPY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, IMAGE-GUIDED; TREATMENT OUTCOME;

EID: 84976317471     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-016-0982-z     Document Type: Article

References (36)

1. Grosu A‑L, Piert M, Weber MA et al (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181(8):483–499
2. Wondergem M, Zant FM van der, Poeg T van der et al (2013) A literature review of 18 F-fluoride PET/CT and 18 F-choline or 11 C-cholie PET/CT for detection of bone metastasis in patients with prostate cancer. Nucl Med Commun 34(10):935–945
3. Umbehr MH, Müntener M, Hany T et al (2013) The role of 11 C-choline and 18 F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64(1):106–117
4. Decaestecker K, Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 12(9):135. doi:10.1186/1748-717X-9-135
5. Eyben FE von, Kairemo K (2014) Meta-analysis of 11 C-choline and 18 F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 35(3):221–230
6. Picchio M, Berardi G, Fodor A et al (2014) (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41(7):1270–1279
7. Jackson WC, Johnson SB, Feng FY et al (2015) Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol 38(4):367–372
8. Ost P, Decaestecker K, Lambert B et al (2013) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74(3):297–305
9. Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583
10. Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13(8):951–962
11. Chang SS, O’Keefe DS, Bacich DJ et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5(10):2674–2681
12. Afshar-Oromieh A, Zechman CM, Malcher A et al (2014) Comaparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Mol Imaging 41(1):11–20
13. Weineisen M, Schottelius M, Simecek J et al (2015) 68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56(8):1169–1176
14. 68GA] CPCR4.2. Nucl Med Biol 41(1):84–89
15. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 16 Oct 2015
16. Pavy JJ, Denekamp J, Letschert J et al (1995) EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31(5):1043–1047
17. Schweizer MT, Zhou XC, Wang H et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886
18. Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209
19. Giesel FL, Fiedler H, Stefanova M et al (2015) PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68 Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(12):1794–1800
20. Cimitan M, Bortulus R, Morassut S et al (2006) [18 F]fluorcholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33(12):1387–1398
21. Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42(8):1784–1794
22. Merseburger AS, Hammerer P, Rozet F et al (2014) Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy. World J Urol 33(8):1079–1085
23. Punnen S, Cooperberg MR, D’Amic AV et al (2013) Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 64(6):905–915
24. Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary salvage therapy for prostate cancer: likelihood, patterns of care, outcomes. Cancer 112(2):307–314
25. Yu EY, Gulati R, Telesca D et al (2010) Duration of first off-treatment interval is prognostic for time to castration resistance an death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28(16):2668–2673
26. Bhandari MS, Crook J, Hussain M (2005) Should intermittent androgen deprivation be uses routinely in clinical practice? J Clin Oncol 23(32):8212–8218
27. Jilg CA, Rischke HC, Reske SN (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188(6):2190–2197
28. Rischke HC, Schultze-Seemann, Wieser G et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191(4):310–320
29. Suardi N, Gandaglia G, Gallina A et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309
30. Rinnab L, Mottaghy FM, Simon J et al (2008) [11 C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197
31. Casamassima F, Masi L, Menichelli C et al (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97(1):49–55
32. Jereczek-Fossa BA, Beltramo G et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897
33. Muacevic A, Kufeld M, Bist C et al (2011) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases in prostate cancer patients. Urol Oncol 31(4):455–460
34. Schick U, Jorcano S, Nouet P et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasis. Acta Oncol 52(8):1622–1628
35. Ahmed KA, Barney BM, Davis BJ et al (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 22(2):215. doi:10.3389/fonc.2012.00215
36. Niyazi M, Bartenstein P, Belka C et al (2010) Choline PET based dose-painting in prostate cancer – modelling of dose effects. Radiat Oncol 18(5):23. doi:10.1186/1748-717X-5-23